• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA approves trial for low-risk patients with MDT’s CoreValve Evolut R

FDA approves trial for low-risk patients with MDT’s CoreValve Evolut R

February 22, 2016 By Brad Perriello

Medtronic's CoreValve Evolut R TAVRMedtronic (NYSE:MDT) said today that the FDA granted an investigational device exemption for a clinical trial of its CoreValve Evolut R implantable heart valve in patients at low risk for adverse events from traditional heart valve replacement surgery.

The expanded indication means a likely spring debut for the 1,200-patient trial in patients with severe aortic stenosis with a less than 3% chance of dying with surgical valve replacement. The CoreValve Evolut R is a transcatheter aortic valve implant that’s already been approved in the U.S. for high- and extreme-risk patient cohorts.

The primary endpoint for the trial is slated to be all-cause mortality or disabling stroke at 2 years, but includes a provision for a 1-year analysis for early submission to the FDA, Fridley, Minn.-based Medtronic said. The study is also designed to evaluate a sub-group of 400 patients for leaflet mobility, a complication associated with the risk for blood clots that prompted an FDA warning late last year.

Enrollment in the trial is due to begin this spring, the company said.

“Medtronic is committed to expanding access to [transcatheter aortic valve replacement] for patients who may benefit based on a robust clinical evidence portfolio,” heart valve therapies general manager Rhonda Robb said in prepared remarks. “We are excited to partner with such proven heart teams to study the CoreValve Evolut R self-expanding platform in this low risk patient population.”

“This trial comes on the heels of data showing patients who underwent TAVR with this self-expanding platform demonstrated superior survival benefit -with low and stable stroke rates- compared to SAVR patients,” added principal investigator Dr. Michael Reardon of the Houston Methodist DeBakey Heart & Vascular Center. “This study is an important next step in developing robust clinical evidence to help heart teams understand the potential benefits of TAVR in a broader patient population.”

Earlier this month, the FDA granted an expanded indication for the CoreValve devices for patients with end-stage renal disease and low-grade, low-flow aortic stenosis.

Filed Under: Cardiovascular, Clinical Trials, Food & Drug Administration (FDA), Regulatory/Compliance, Replacement Heart Valves Tagged With: Medtronic

More recent news

  • Penumbra completes enrollment in pulmonary embolism trial
  • Zoll opens new facility in Rhode Island
  • FDA expands clearance for Inquis Medical’s Aventus thrombectomy system
  • SS Innovations completes first robotic cardiac surgery in the Americas
  • GI Windows wins FDA nod for magnet tech

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy